Sector: Health Care
Director information for GENEDX HOLDINGS CORP CLASS A
Board as disclosed in the proxy statement filed April 30, 2026. Titles and roles are as stated in that filing and may have changed since.
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Eli D. Casdin | 53 | ["Diagnostics / Medical Device / Biotechnology","Executive Leadership / C-Suite","Corporate Governance"] | [] | 2026 | |
| Emily Leproust, Ph.D. | 53 | ["Diagnostics / Medical Device / Biotechnology","Executive Leadership / C-Suite","Business Operations","Business Development / Sales","Corporate Governance","Cybersecurity","Scientific / Research","Technology and AI","Talent Development","Risk Management"] | [] | 2026 | |
| Joshua Ruch | 76 | ["Diagnostics / Medical Device / Biotechnology","Executive Leadership / C-Suite","Corporate Governance","Cybersecurity","Technology and AI","Risk Management"] | [] | 2026 | |
| Katherine Stueland | ["Diagnostics / Medical Device / Biotechnology","Executive Leadership / C-Suite","Business Operations","Business Development / Sales","Corporate Governance","Cybersecurity","Talent Development","Risk Management"] | [] | 2026 | ||
| Keith Meister | 53 | ["Diagnostics / Medical Device / Biotechnology","Executive Leadership / C-Suite","Finance / Accounting","Business Operations","Corporate Governance","Cybersecurity","Risk Management"] | [] | 2026 | |
| Richard C. Pfenniger, Jr. | 70 | ["Diagnostics / Medical Device / Biotechnology","Executive Leadership / C-Suite","Finance / Accounting","Business Operations","Corporate Governance","Cybersecurity","Talent Development"] | [] | 2026 | |
| Thomas Fuchs, Ph.D. | 47 | ["Diagnostics / Medical Device / Biotechnology","Executive Leadership / C-Suite","Strategic Planning","Corporate Governance","Cybersecurity","Talent Development","Risk Management"] | [] | 2026 |
